fda spravato - Search News

FDA Approves ‘Spravato’ Nasal Spray

FDA-approved nasal spray for severe depression can lead to remission

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in people who have not responded to at least two oral antidepressants.

Renal & Urology News · 4h

FDA Approves Spravato Nasal Spray for Treatment-Resistant Depression

(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least 2 oral antidepressants, according to a news release issued by Johnson & Johnson.

Popular Science · 5d

FDA approves first-of-its-kind nasal spray for severe depression

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar psychiatric conditions.

6d

J&J's Spravato Wins FDA Approval, Stands as a Game-Changer for Mental Health Care

New Brunswick, NJ January 21, 2025 Johnson & Johnson ( NYSE:JNJ) has finally got its breakthrough depression treatment, ...

Boing Boing on MSN3d

FDA approves J&J's patented psychedelic esketamine for depression without requiring you take other antidepressants with it

On Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results